Hibsago (bepirovirsen)
GlaxoSmithKline (GSK)
ApprovedOct 20, 2026
Marketer take
An antisense add-on used with existing antiviral therapy in chronic hepatitis B, a market long limited to oral suppressive drugs, so hepatologist and ID education on which patients qualify will be central.
- Sponsor company
- GlaxoSmithKline (GSK)
- Indication
- To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
- Therapeutic area
- Infectious disease
- Event
- FDA approval
- Date
- Oct 20, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?